

Hydroxyurea (Hydroxycarbamide) - Guidelines for treating patients with Sickle Cell Disease

Version:	1	Date:	4 th May 2010
Authors:	David Rees, Sue Height, Sandra O'Driscoll		
Responsible committee or Director:	Child Health		
Review date:	April 2012		
Target audience:	Paediatricians, paediatric haematologists, haematologists		
Stakeholders/ committees involved in guideline development :	Paediatricians, paediatric haematologists, haematologists		

For Clinical Guidelines Groups' use only

Hydroxyurea (Hydroxycarbamide) - Guidelines for treating patients with Sickle Cell Disease

This guideline is aimed at all children in King's College Hospital with Sickle Cell Disease who are taking or might take hydroxyurea (also called hydroxycarbamide). The guideline applies to patients with sickle cell disease who are currently under the care of the Paediatric Haematology team. It is mainly aimed at being a tool for the medical team managing these patients, but any member of the multidisciplinary team may find it useful.

1. Patient selection

Each patient must be evaluated carefully before starting hydroxyurea. In general, it should be considered when patients are having significant problems related to their condition. It is mostly used in children with sickle cell anaemia (HbSS) and HbS/ β thalassaemia, but may also be useful in other types of sickle cell disease such as HbSC disease. The two main indications at the moment are:

- (a) more than three episodes of acute pain each year, which are causing significant disruption to education, or family life.
- (b) recurrent or severe acute chest syndrome

Other less established indications include:

- (a) conditional velocities on transcranial Doppler scans
- (b) significant cerebral vasculopathy when blood transfusions are unacceptable
- (c) progressive cerebral vasculopathy despite adequate blood transfusions
- (d) persistent low haemoglobin (<6g/dl)
- (e) hypoxaemia
- (f) significant proteinuria
- (g) patients keen to avoid blood transfusions if at all possible
- (h) preoperative preparation when blood transfusions are not acceptable

The patients with less established indications should be discussed at the Multidisciplinary meeting before starting.

2. Parent information and Consent

Parent information leaflets are available and should be given to parents in addition to a full discussion of risks, benefits and possible side effects, including possible bone marrow damage and subfertility. Many parents and families may want to think about the issues and discuss things further, and a follow-up appointment in 2-4 weeks should be offered. Possible irreversible subfertility should be discussed with the parents of all boys considering hydroxyurea. Hydroxyurea is a mild form of chemotherapy and informed consent is essential; discussions should be recorded in the notes but it is not necessary for the child or parent to sign anything. Both males and females should be advised about the theoretical risk of teratogenicity, and the need to avoid becoming pregnant or conceiving a child whilst taking hydroxyurea.

3. Baseline investigations

Prior to commencing hydroxyurea these should include:

FBC and reticulocytes

HbF%
Renal function
Hepatic function including ALT

4. **Recommended Dose**

The starting dose is about 15mg/kg once daily, and the maximum dose is 35mg/kg daily. The dose is typically increased by 5mg/kg every 2-3 months until there is evidence of clinical benefit. For most patients, the lowest effective dose as assessed by clinical improvement is used. However, for some indications, such as those involving cerebrovascular disease, the dose should be increased until limited by myelosuppression.

5. **Formulation**

Hydroxyurea is available as 500mg capsules and liquid. Liquid is often most suitable for children under the age of seven years, although it has a short-shelf life, and can be difficult to obtain from local hospitals for shared-care patients. It is possible to arrange for local hospitals or pharmacies to dispense the drug, and this should be discussed with the pharmacy here.

It is possible to open hydroxyurea capsules and give the powder to the child with a small amount of water or juice. This works well for some parents but it should be explained that hydroxyurea is a form of chemotherapy and should not come into contact with skin or anybody other than the patient; this will mean washing the spoon very carefully and wiping up any spills immediately.

Because the capsules only come as 500mg, it is sometimes difficult to give the exact calculated dose or increment; in general it is satisfactory to give alternating day doses such as 500mg alternating with 1g, although this should be explained carefully to the carers and child.

6. **Monitoring of Patients**

Order sets are on EPR under paediatrics/haematology

- Sandra O'Driscoll should be informed of all patients starting hydroxyurea to allow them to be included on the list for review in the multidisciplinary meeting.
- FBC, reticulocytes, renal and hepatic function should be checked 2 weeks after starting.
- FBC, reticulocytes, HbF%, renal and hepatic function should be checked every 1-3months.
- If the dose is increased, blood tests should be performed after two weeks on the higher dose, before resuming 1-3 monthly monitoring.
- Patients on hydroxyurea should still have annual review blood tests and investigations performed, including transcranial Doppler scanning.
- Contact the family directly and inform the GP about any dose adjustments based on the blood test results.
- Stop hydroxyurea if toxicity occurs – contact the family directly with instructions and arrange further tests to monitor recovery. Markers of toxicity include:

Haematological:

Neutrophils < $1.0 \times 10^9/l$
Platelets < $80 \times 10^9/l$
Reticulocytes < $80 \times 10^9/l$

Renal:

≥ 50% or more increase in serum creatinine

Hepatic

> 100% increase in ALT

7. Admission to hospital

Hydroxyurea should be continued during an admission unless the blood results indicate bone marrow suppression or the patient is septic.

8. Withdrawal of Hydroxyurea

Patients should usually be treated for at least six months before deciding to stop hydroxyurea because of lack of benefit. When hydroxyurea is associated with clinical improvement, it is typically continued for at least 2-3 years; consideration is then given to stopping it, depending on the initial indications, the views of the child and carers, and circumstances at that time. In general it is better to stop hydroxyurea during school holidays and not just before important events such as exams.

References

1. Charache S, Terrin ML, Moore RD, et al. Effect of hydroxyurea on frequency of painful crises in sickle cell anemia. *N Engl J Med* 1995; **332**: 1317-22.
2. Strouse JJ, Lanzkron S, Beach MC et al. Hydroxyurea for sickle cell disease: a systematic review for efficacy and toxicity in children. *Pediatrics* 2008; **122**: 1332-42.
3. Berthaut I, Guignedoux G, Kirsch-Noir F et al. Influence of sickle cell disease and treatment with hydroxyurea on sperm parameters and fertility of human males. *Hematologica* 2008; **93**: 988-93.
4. Zimmerman SA, Schultz WH, Burgett S, Mortier NA, Ware RE. Hydroxyurea therapy lowers transcranial Doppler flow velocities in children with sickle cell anemia. *Blood* 2007; **110**: 1043-47.
5. Singh SA, Koumbourlis AC, Aygun B. Resolution of chronic hypoxemia in pediatric sickle cell patients after treatment with hydroxyurea. *Pediatr Blood Cancer* 2008; **50**: 1258-60.
6. Fitzhugh CD, Wigfall DR, Ware RE. Enalapril and hydroxyurea therapy for children with sickle nephropathy. *Pediatr Blood Cancer* 2005; **45**: 982-85.

David Rees
Sue Height
Sandra O'Driscoll